Belite Bio (NASDAQ:BLTE) Announces Quarterly Earnings Results

Belite Bio (NASDAQ:BLTEGet Free Report) posted its earnings results on Monday. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02), Zacks reports.

Belite Bio Stock Down 3.0 %

Shares of BLTE stock opened at $67.44 on Monday. Belite Bio has a 12 month low of $31.01 and a 12 month high of $86.53. The company’s fifty day simple moving average is $58.40 and its 200-day simple moving average is $60.33. The firm has a market cap of $2.15 billion, a PE ratio of -60.76 and a beta of -1.54.

Analysts Set New Price Targets

Separately, Benchmark increased their price objective on shares of Belite Bio from $57.00 to $79.00 and gave the stock a “buy” rating in a research report on Tuesday, January 21st.

Get Our Latest Stock Analysis on BLTE

About Belite Bio

(Get Free Report)

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.

Read More

Earnings History for Belite Bio (NASDAQ:BLTE)

Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.